|
Michael Kranda joined Anesiva as President and Chief Executive Officer in June of 2008. Prior to Anesiva Mr. Kranda led life sciences venture investments as Managing Director for Vulcan Capital. From July 1996 to July 2002 Mr. Kranda served as chief executive officer at Oxford GlycoSciences establishing the biotechnology company as the leading proteomics platform-based drug discovery company. Prior to joining Oxford GlycoSciences Mr. Kranda was president and chief operating officer at Immunex Corporation (now Amgen) where he was responsible for sales and marketing manufacturing and operations. Mr. Kranda serves on the boards of PTC Therapeutics Cumbre Pharmaceuticals BiPar Sciences Nura Inc. Raven Biotechnologies and the Washington State Biotechnology Business Association. Mr. Kranda received his B.A. and M.B.A from University of Washington School of Business.
| 